Protein phosphatase PP2A activation by formoterol reverses corticosteroid insensitivity Source: Annual Congress 2009 - Airway cell biology Year: 2009
Formoterol restores oxidative stress-induced corticosteroid insensitivity via activation of protein phosphatase PP2A Source: Annual Congress 2012 - Cellular signalling mechanisms in the airways Year: 2012
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017
Activated protein phosphatase PP2A by formoterol enhances nuclear translocation of glucocorticoid receptor induced by budesonide Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Effect of rifampin, a potent organic-anion-transporting polypeptide inhibitor (OATPi), on the PK of BMS-986278, a lysophosphatidic acid receptor (LPA1) antagonist Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Inhibition of inflammatory gene expression by dexamethasone partly depends on the phosphatase, MKP-1 (DUSP1) Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Corticosteroids: use and insensitivity in severe asthma Source: Eur Respir Mon 2011; 51: 236-252 Year: 2011
A novel target of formoterol, a dual-specificity phosphatase DUSP4 on regulation of corticosteroid budesonide sensitivity Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Impaired protein tyrosine phosphatase PTPRR reduces response to corticosteroid in mononuclear cells Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
MAP kinase phosphatase 1 mediates glucocorticoid inhibition of CD38 expression in human airway smooth muscle Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Role of protein phosphatase 1 glycogen-associated regulatory subunit in asthma Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018